Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCCNASDAQ:MGNXNASDAQ:VIRINASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$1.47-6.7%$3.88$1.44▼$49.34$22.56M0.52107,415 shs169,655 shsMGNXMacroGenics$1.57+5.0%$1.51$0.99▼$5.77$98.74M2.2681,051 shs202,946 shsVIRIVirios Therapeutics$5.33-2.5%$4.95$0.13▼$1.04$102.65M1.581.05 million shs55,839 shsVTYXVentyx Biosciences$1.86+21.2%$1.20$0.78▼$5.66$132.72M0.731.32 million shs7.20 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-10.29%-32.33%-53.52%-71.64%-95.64%MGNXMacroGenics-5.10%-3.87%+7.19%-48.26%-65.02%VIRIVirios Therapeutics+2.73%+12.68%+27.99%-9.37%+2,874.96%VTYXVentyx Biosciences-3.77%+29.66%+35.40%-7.83%-67.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals0.4931 of 5 stars0.02.00.00.02.22.50.0MGNXMacroGenics3.5591 of 5 stars3.21.00.04.41.62.50.6VIRIVirios TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVTYXVentyx Biosciences2.2772 of 5 stars3.41.00.00.03.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AMGNXMacroGenics 2.40Hold$6.13291.37% UpsideVIRIVirios Therapeutics 2.50Moderate Buy$3.00-43.71% DownsideVTYXVentyx Biosciences 2.75Moderate Buy$10.00439.08% UpsideCurrent Analyst Ratings BreakdownLatest CYCC, VTYX, VIRI, and MGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.003/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$14K1,611.19N/AN/A$0.57 per share2.57MGNXMacroGenics$152.43M0.65N/AN/A$2.46 per share0.64VIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AVTYXVentyx BiosciencesN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$56.00N/A∞N/A-18,150.00%-1,901.11%-188.23%N/AMGNXMacroGenics-$9.06M-$0.89N/AN/AN/A-69.07%-89.42%-38.57%8/5/2025 (Estimated)VIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)VTYXVentyx Biosciences-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%N/ALatest CYCC, VTYX, VIRI, and MGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48-$0.39+$0.09-$0.39N/AN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 million2/27/2025Q4 2024VTYXVentyx Biosciences-$0.54-$0.41+$0.13-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel Pharmaceuticals$0.1510.24%N/AN/A N/AMGNXMacroGenicsN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ALatest CYCC, VTYX, VIRI, and MGNX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.770.77MGNXMacroGenicsN/A3.753.69VIRIVirios TherapeuticsN/A7.277.27VTYXVentyx BiosciencesN/A23.5223.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%MGNXMacroGenics96.89%VIRIVirios Therapeutics9.05%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals68.00%MGNXMacroGenics13.00%VIRIVirios Therapeutics12.20%VTYXVentyx Biosciences14.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals1415.40 million4.78 millionOptionableMGNXMacroGenics43063.09 million55.67 millionOptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableVTYXVentyx Biosciences3071.16 million57.86 millionOptionableCYCC, VTYX, VIRI, and MGNX HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Takes $3.90 Million Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 22 at 4:42 AM | marketbeat.comVestal Point Capital LP Acquires 275,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 21 at 8:14 AM | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Deerfield Management Company L.P. Series CMay 10, 2025 | marketbeat.comVentyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate ProgressMay 8, 2025 | globenewswire.comWhy Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%May 7, 2025 | aaii.comSusquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 6, 2025 | marketbeat.comGreat week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous yearMay 4, 2025 | finance.yahoo.comVentyx Biosciences (VTYX) Projected to Post Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $690,000 Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)May 2, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)April 30, 2025 | marketbeat.comVentyx Biosciences announces seven additional appointments to SABApril 2, 2025 | markets.businessinsider.comVentyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease SpecialistsApril 1, 2025 | globenewswire.comVentyx Biosciences Reports 2024 Financial Results and ProgressMarch 4, 2025 | tipranks.comVentyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory ChallengesMarch 1, 2025 | tipranks.comH.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)February 28, 2025 | markets.businessinsider.comVentyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate ProgressFebruary 27, 2025 | globenewswire.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025February 18, 2025 | markets.businessinsider.comVentyx Biosciences’ VTX958 shows efficacy in Crohn’s DiseaseFebruary 18, 2025 | markets.businessinsider.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025February 18, 2025 | globenewswire.comVentyx Biosciences stock hits 52-week low at $1.57February 12, 2025 | msn.comVentyx Biosciences Inc (VTYX) Stock Settles at $1.84: What’s Contributing to This Price Point?February 5, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCC, VTYX, VIRI, and MGNX Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$1.46 -0.11 (-6.69%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.MacroGenics NASDAQ:MGNX$1.56 +0.08 (+5.03%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Virios Therapeutics NASDAQ:VIRI$5.33 -0.14 (-2.47%) As of 05/21/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Ventyx Biosciences NASDAQ:VTYX$1.86 +0.33 (+21.24%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
